Aspirin use and cardiovascular outcome in patients with type 2 diabetes mellitus and heart failure

A population-based cohort study

Research output: Contribution to journalArticle

Abstract

Background-Aspirin is of uncertain benefit for primary prevention in patients with type 2 diabetes mellitus (T2D). We assessed whether primary prevention with aspirin is beneficial in patients with T2D and heart failure (HF). Methods and Results-Data from The Health Improvement Network, a UK multicenter prospective primary care database, were analyzed. Those with T2D and HF, age ≥55 years, and no previous history of myocardial infarction and/or coronary artery disease, stroke, peripheral artery disease, or atrial fibrillation were included. We compared outcomes for those on aspirin to no aspirin after diagnosis of HF and T2D and assessed the role of a >75-mg dose. The primary outcome was a composite of all-cause mortality and hospitalization for HF; secondary outcomes were nonfatal stroke, nonfatal myocardial infarction, or major bleeding. There were 5967 participants on aspirin and 6567 not on aspirin. The mean age (SD) was 75.3 (9.6) years, 53.9% were men, and the mean follow-up (SD) was for 5 (4.2) years. After propensity-score matching and further multivariable adjustment, aspirin was significantly associated with a decrease in the primary outcome and all-cause mortality (hazard ratio=0.88, 95% confidence interval 0.82-0.93; 0.88, 0.83-0.94], respectively); and an increased risk of nonfatal myocardial infarction (hazard ratio=1.66; 95% confidence interval 1.49-1.85) and nonfatal stroke (hazard ratio=1.23, 1.01-1.50). Major bleedings and hospitalization for HF were not significantly higher with aspirin (hazard ratio=0.68, 0.45-1.03; 0.87, 0.66-1.15, respectively). There was no additional benefit for a dose >75 mg. Conclusions-Primary prevention with aspirin in patients with T2D and HF is associated with lower all-cause mortality.

Original languageEnglish
Article numbere010033
JournalJournal of the American Heart Association
Volume7
Issue number21
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint

Type 2 Diabetes Mellitus
Aspirin
Cohort Studies
Heart Failure
Population
Primary Prevention
Stroke
Myocardial Infarction
Mortality
Hospitalization
Confidence Intervals
Hemorrhage
Propensity Score
Peripheral Arterial Disease
Atrial Fibrillation
Coronary Artery Disease
Primary Health Care
Databases
Health

Keywords

  • Aspirin
  • Death
  • Diabetes mellitus
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{f50eb8bc454f42fdb76406d9bf01297d,
title = "Aspirin use and cardiovascular outcome in patients with type 2 diabetes mellitus and heart failure: A population-based cohort study",
abstract = "Background-Aspirin is of uncertain benefit for primary prevention in patients with type 2 diabetes mellitus (T2D). We assessed whether primary prevention with aspirin is beneficial in patients with T2D and heart failure (HF). Methods and Results-Data from The Health Improvement Network, a UK multicenter prospective primary care database, were analyzed. Those with T2D and HF, age ≥55 years, and no previous history of myocardial infarction and/or coronary artery disease, stroke, peripheral artery disease, or atrial fibrillation were included. We compared outcomes for those on aspirin to no aspirin after diagnosis of HF and T2D and assessed the role of a >75-mg dose. The primary outcome was a composite of all-cause mortality and hospitalization for HF; secondary outcomes were nonfatal stroke, nonfatal myocardial infarction, or major bleeding. There were 5967 participants on aspirin and 6567 not on aspirin. The mean age (SD) was 75.3 (9.6) years, 53.9{\%} were men, and the mean follow-up (SD) was for 5 (4.2) years. After propensity-score matching and further multivariable adjustment, aspirin was significantly associated with a decrease in the primary outcome and all-cause mortality (hazard ratio=0.88, 95{\%} confidence interval 0.82-0.93; 0.88, 0.83-0.94], respectively); and an increased risk of nonfatal myocardial infarction (hazard ratio=1.66; 95{\%} confidence interval 1.49-1.85) and nonfatal stroke (hazard ratio=1.23, 1.01-1.50). Major bleedings and hospitalization for HF were not significantly higher with aspirin (hazard ratio=0.68, 0.45-1.03; 0.87, 0.66-1.15, respectively). There was no additional benefit for a dose >75 mg. Conclusions-Primary prevention with aspirin in patients with T2D and HF is associated with lower all-cause mortality.",
keywords = "Aspirin, Death, Diabetes mellitus, Heart failure",
author = "{Abi Khalil}, Charbel and Omar Omar and {Al Suwaidi}, Jassim and Shahrad Taheri",
year = "2018",
month = "11",
day = "1",
doi = "10.1161/JAHA.118.010033",
language = "English",
volume = "7",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "21",

}

TY - JOUR

T1 - Aspirin use and cardiovascular outcome in patients with type 2 diabetes mellitus and heart failure

T2 - A population-based cohort study

AU - Abi Khalil, Charbel

AU - Omar, Omar

AU - Al Suwaidi, Jassim

AU - Taheri, Shahrad

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background-Aspirin is of uncertain benefit for primary prevention in patients with type 2 diabetes mellitus (T2D). We assessed whether primary prevention with aspirin is beneficial in patients with T2D and heart failure (HF). Methods and Results-Data from The Health Improvement Network, a UK multicenter prospective primary care database, were analyzed. Those with T2D and HF, age ≥55 years, and no previous history of myocardial infarction and/or coronary artery disease, stroke, peripheral artery disease, or atrial fibrillation were included. We compared outcomes for those on aspirin to no aspirin after diagnosis of HF and T2D and assessed the role of a >75-mg dose. The primary outcome was a composite of all-cause mortality and hospitalization for HF; secondary outcomes were nonfatal stroke, nonfatal myocardial infarction, or major bleeding. There were 5967 participants on aspirin and 6567 not on aspirin. The mean age (SD) was 75.3 (9.6) years, 53.9% were men, and the mean follow-up (SD) was for 5 (4.2) years. After propensity-score matching and further multivariable adjustment, aspirin was significantly associated with a decrease in the primary outcome and all-cause mortality (hazard ratio=0.88, 95% confidence interval 0.82-0.93; 0.88, 0.83-0.94], respectively); and an increased risk of nonfatal myocardial infarction (hazard ratio=1.66; 95% confidence interval 1.49-1.85) and nonfatal stroke (hazard ratio=1.23, 1.01-1.50). Major bleedings and hospitalization for HF were not significantly higher with aspirin (hazard ratio=0.68, 0.45-1.03; 0.87, 0.66-1.15, respectively). There was no additional benefit for a dose >75 mg. Conclusions-Primary prevention with aspirin in patients with T2D and HF is associated with lower all-cause mortality.

AB - Background-Aspirin is of uncertain benefit for primary prevention in patients with type 2 diabetes mellitus (T2D). We assessed whether primary prevention with aspirin is beneficial in patients with T2D and heart failure (HF). Methods and Results-Data from The Health Improvement Network, a UK multicenter prospective primary care database, were analyzed. Those with T2D and HF, age ≥55 years, and no previous history of myocardial infarction and/or coronary artery disease, stroke, peripheral artery disease, or atrial fibrillation were included. We compared outcomes for those on aspirin to no aspirin after diagnosis of HF and T2D and assessed the role of a >75-mg dose. The primary outcome was a composite of all-cause mortality and hospitalization for HF; secondary outcomes were nonfatal stroke, nonfatal myocardial infarction, or major bleeding. There were 5967 participants on aspirin and 6567 not on aspirin. The mean age (SD) was 75.3 (9.6) years, 53.9% were men, and the mean follow-up (SD) was for 5 (4.2) years. After propensity-score matching and further multivariable adjustment, aspirin was significantly associated with a decrease in the primary outcome and all-cause mortality (hazard ratio=0.88, 95% confidence interval 0.82-0.93; 0.88, 0.83-0.94], respectively); and an increased risk of nonfatal myocardial infarction (hazard ratio=1.66; 95% confidence interval 1.49-1.85) and nonfatal stroke (hazard ratio=1.23, 1.01-1.50). Major bleedings and hospitalization for HF were not significantly higher with aspirin (hazard ratio=0.68, 0.45-1.03; 0.87, 0.66-1.15, respectively). There was no additional benefit for a dose >75 mg. Conclusions-Primary prevention with aspirin in patients with T2D and HF is associated with lower all-cause mortality.

KW - Aspirin

KW - Death

KW - Diabetes mellitus

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=85056826149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056826149&partnerID=8YFLogxK

U2 - 10.1161/JAHA.118.010033

DO - 10.1161/JAHA.118.010033

M3 - Article

VL - 7

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 21

M1 - e010033

ER -